A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
ConclusionsPsilocybin possesses a multi-domain effectiveness. The field would benefit from highly rigorous proof-of-mechanism research to assess the effects of psilocybin using the RDoC framework. The combined effect of psilocybin with psychosocial interventions with RDoC-based outcomes is a priority therapeutic vista. (Source: CNS Drugs)
Source: CNS Drugs - September 12, 2022 Category: Neurology Source Type: research
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
AbstractInebilizumab (Uplizna®) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive. Inebilizumab targets the B cell antigen CD19 and effectively depletes circulating B cells, thus suppressing inflammatory NMOSD attacks that are potentially disabling or life-threatening. It is approved as an intravenous infusion in several countries. In the pivotal phase 2/3 N-MOmentum trial, inebilizumab reduced the risk of NMOSD attacks compared with placebo, including in AQP4-antibody seropositive patients. Inebilizumab al...
Source: CNS Drugs - September 7, 2022 Category: Neurology Source Type: research
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
ConclusionThese results further extend our knowledge of the effectiveness, specifically regarding improvements in cognitive processing speed, disability and PROs, of long-term natalizumab treatment in early RRMS patients.Clinicaltrials.govNCT01485003 (5 December 2011) (Source: CNS Drugs)
Source: CNS Drugs - September 5, 2022 Category: Neurology Source Type: research
New Oral Drugs for Migraine
AbstractMigraine is a common and disabling neurological disorder, with several manifestations, of which pain is just one. Despite its worldwide prevalence, there remains a paucity of targeted and effective treatments for the condition, leaving many of those affected underserved by available treatments. Work over the last 30+ years has recently led to the emergence of the first targeted acute and preventive treatments in our practice since the triptan era in the early 1990s, which are changing the landscape of migraine treatment. These include the monoclonal antibodies targeting calcitonin gene-related peptide or its recept...
Source: CNS Drugs - August 29, 2022 Category: Neurology Source Type: research
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
(Source: CNS Drugs)
Source: CNS Drugs - August 17, 2022 Category: Neurology Source Type: research
Correction to: Antiseizure Drugs and Movement Disorders
(Source: CNS Drugs)
Source: CNS Drugs - August 17, 2022 Category: Neurology Source Type: research
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability
AbstractStatus epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings. Benzodiazepines (BZDs) are the first-line treatment for SE worldwide due to their efficacy, tolerability, and rapid onset of action. Although all BZDs act as allosteric modulators at the inhibitory gamma-aminobutyric acid (GABA)A receptor, the individual agents have different efficacy profiles and pharmacokinetic and pharmacodynamic propert...
Source: CNS Drugs - August 16, 2022 Category: Neurology Source Type: research
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
In conclusion, onasemnogene abeparvovec represents an important treatment option for patients with SMA, particularly when initiated early in the course of the disease. (Source: CNS Drugs)
Source: CNS Drugs - August 12, 2022 Category: Neurology Source Type: research
Treatment Options in Refractory Autoimmune Encephalitis
AbstractAutoimmune encephalitis represents a potentially treatable immune-mediated condition that is being more frequently recognized. Prompt immunotherapy is a key factor for the management of autoimmune encephalitis. First-line treatments include intravenous steroids, plasma exchange, and intravenous immunoglobulins, which can be combined in most severe cases. Rituximab and cyclophosphamide are administered as second-line agents in unresponsive cases. A minority of patients may still remain refractory, thus representing a major clinical challenge. In these cases, treatment strategies are controversial, and no guidelines ...
Source: CNS Drugs - August 2, 2022 Category: Neurology Source Type: research
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval
This article summarizes the milestones in the development of sodium phenylbutyrate/ursodoxicoltaurine leading to this first approval. (Source: CNS Drugs)
Source: CNS Drugs - July 30, 2022 Category: Neurology Source Type: research
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
ConclusionsTreatment with viloxazine ER resulted in a statistically significant improvement in primary and key secondary endpoints, indicating improvements in attention-deficit/hyperactivity disorder symptomology, executive function, and overall clinical illness severity in adults. Viloxazine ER was well tolerated at the tested doses in adults with attention-deficit/hyperactivity disorder.Clinical Trial RegistrationClinicaltrials.gov identifier: NCT04016779. (Source: CNS Drugs)
Source: CNS Drugs - July 27, 2022 Category: Neurology Source Type: research
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis
(Source: CNS Drugs)
Source: CNS Drugs - July 25, 2022 Category: Neurology Source Type: research
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments
AbstractMultiple sclerosis treatment made substantial headway during the last two decades with the implementation of therapeutics with new modes of action and routes of application. We are now in the situation that second-generation molecules, approved since 2018, are on the market, characterized by reduced side effects using a more tailored therapeutic approach. Diroximel fumarate is a second-generation fumarate with reduced gastrointestinal side effects. Moreover, several novel, selective, sphingosine-1-phosphate receptor modulators with reduced off-target effects have been developed; namely siponimod, ozanimod, and pone...
Source: CNS Drugs - July 22, 2022 Category: Neurology Source Type: research
Antiseizure Drugs and Movement Disorders
AbstractThe relationship between antiseizure drugs and movement disorders is complex and not adequately reviewed so far. Antiseizure drugs as a treatment for tremor and other entities such as myoclonus and restless leg syndrome is the most common scenario, although the scientific evidence supporting their use is variable. However, antiseizure drugs also represent a potential cause of iatrogenic movement disorders, with parkinsonism and tremor the most common disorders. Many other antiseizure drug-induced movement disorders are possible and not always correctly identified. This review was conducted by searching for all the ...
Source: CNS Drugs - July 21, 2022 Category: Neurology Source Type: research
The Options for Neuraxial Drug Administration
AbstractNeuraxial drug administration, i.e., the injection of drugs into the epidural or intrathecal space to produce anesthesia or analgesia, is a technique developed more than 120 years ago. Today, it still is widely used in daily practice in anesthesiology and in acute and chronic pain therapy. A multitude of different drugs have been introduced for neuraxial injection, only a part of which have obtained official approval for that indication. A broad understanding of the pharmacology of those agents is essential to the clinician to utilize them in a safe and efficient manner. In the present narrative review, we summariz...
Source: CNS Drugs - July 15, 2022 Category: Neurology Source Type: research
